January 14, 2020 /3BL Media/ - There is increasing pressure on companies to disclose accurate data on impacts against material social and environmental issues - plus the future risks and opportunities that the company faces. ESG information on companies is being utilised as a guide to the movement of capital. ESG is becoming mainstream.
Johnson & Johnson, in Partnership With Pyxera Global, Launches Its Third Global Pro Bono Year With the New Orleans Mayor Engaged
April 30, 2019 /3BL Media/ — The Mayor of New Orleans, LaToya Cantrell, welcomed the Johnson & Johnson Global Pro Bono team to New Orleans for the program’s official kickoff event at City Hall on April 29. Johnson & Johnson has designed its Global Pro Bono program in collaboration with PYXERA Global to tackle healthcare and community issues by harnessing the power of its most powerful resource—its people. The mayor’s attendance shows that the city believes cross-sector partnerships are needed to improve the lives of the citizens of New Orleans.
American cities, consumer goods companies, and retailers are facing a financial and environmental crisis: we are currently spending billions of dollars to landfill products and packaging when, instead, they could be sold to the recycling industry. These valuable commodities could be recycled, drive costs efficiency, and create jobs. There are many benefits to recycling including the reduction in manufacturing costs for consumer goods, reduction in landfill disposal costs, increased revenue for municipalities, and creation of local jobs.
From Berkley Pollard, Director, Clinical Quality Assurance, Johnson & Johnson Vision Care, Inc.
Recently, I attended the National Urban League conference (NUL) in New Orleans to help with a program sponsored by Johnson & Johnson Vision Care, Inc., which offered free vision evaluations to the neighboring communities.
From Paul Stoffels, Worldwide Chairman, Pharmaceuticals Group, Johnson & Johnson
The fight against HIV has been part of my life’s work and one of my greatest passions. I first met this enemy as a young physician in training in Africa in the early 1980s. Today, as Worldwide Chairman of the Pharmaceuticals Group of Johnson & Johnson, I am privileged to be part of a company whose purpose is caring for people.
From John Wilson, Vice President, Oncology Sales & Marketing, Janssen Biotech, Inc.
Any trip into unfamiliar terrain can be daunting, particularly if you are without the aid of critical information such as guide books, GPS or at the very least, a map to navigate the way. This is especially true if the journey you are about to embark on is a cancer diagnosis.
(3BL Media) June 4, 2012 - With thousands of new drugs and medicines entering the market every year and chemistry touching nearly every part of our lives, there is an urgent need to develop chemical compounds in a responsible and sustainable manner.
Company Expands Environmentally-Preferred Offerings to 30 Products in its EARTHWARDS™ Portfolio
(3BL Media / theCSRfeed) New Brunswick, NJ – March 1, 2012 – Johnson & Johnson added 19 new products to its EARTHWARDS™ portfolio - 15 in 2011 and four to date in 2012. EARTHWARDS™ is an internal process used by the company’s product teams to innovate better products with smaller environmental footprints.